MU · Investment summary · as of 3 August 2026
Priced for an operating path the record does not support
Business type: Transition · cyclical or commodity-sensitive
The operating path required by today's price is not achievable on the evidence.
At $829.01, MU requires a 37% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 7%.
declared: the margin axis has no solution at demonstrated growth; the disagreement with the market is the growth/persistence of the revenue supercycle. The margin regime becomes the axis only after granting consensus FY2027 in full (then: permanent 50.2% required).
The value rests on an exit multiple of 8.7x, a terminal operating margin of 38% and a 13.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: CY2027 supply wave (own >$40bn FY2027 capex, industry adds, HBM packaging 1H CY2027) into decelerating AI capex; merchant prices break (60-75% of book unprotected); SCA CEILINGS, not floors, become the binding constraint.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | declared: the margin axis has no solution at demonstrated growth; the disagreement with the market is the growth/persistence of the revenue supercycle. |
| What do we forecast? | Revenue growth of 7% demonstrated; a terminal operating margin of 38%; an exit multiple of 8.7x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -29.6 percentage points. |
| What is it worth? | Twelve-month target $933.00, +13% from the struck price. Scenario-weighted expected return net of costs +12.6%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 30 September 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
CY2027 supply wave (own >$40bn FY2027 capex, industry adds, HBM packaging 1H CY2027) into decelerating AI capex; merchant prices break (60-75% of book unprotected); SCA CEILINGS, not floors, become the binding constraint. Merchant tranche halves (FY2023 analog -49.5%), SCA floor $20bn/yr holds, blended mid-cycle margin 25%, valued 3y out at the identity floor 7.3x.
Estimated probability 25%, against the 11% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
trim/exit when 12m forward E[R] < 0 at unchanged estimates On approach to the $933.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | CY2027 supply wave (own >$40bn FY2027 capex, industry adds, HBM packaging 1H CY2027) into decelerating AI capex; merchant prices break (60-75% of book unprotected); SCA CEILINGS, not floors, become the binding constraint. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -29.6 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: CY2027 supply wave (own >$40bn FY2027 capex, industry adds, HBM packaging 1H CY2027) into decelerating AI capex; merchant prices break (60-75% of book unprotected); SCA CEILINGS, not floors, become the binding constraint. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $621.76, which forces an immediate review.